Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR2 | Q16832 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | FASN | P49327 | 4/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | BRAF | P15056 | 1/20 | 0.44 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1229935 | 0.95 | MAPK14 (0.50) | DDR2FASNMAPK14SLC2A1PPARG | |
| SCHEMBL1140453 | 0.93 | DDR2 (0.49) | DDR2MAPTFASNMAPK14PPARG | |
| SCHEMBL1140460 | 0.93 | DDR2 (0.48) | DDR2KDM4EMAPTFASNMAPK14 | |
| SCHEMBL1140493 | 0.93 | DDR2 (0.48) | DDR2MAPTFASNMAPK14RAB9A | |
| SCHEMBL1140359 | 0.92 | DDR2 (0.53) | DDR2FASNMAPK14RAB9AL3MBTL1 | |
| SCHEMBL1140351 | 0.90 | HIF1A (0.51) | DDR2MAPTFASNMAPK14PPARG | |
| SCHEMBL1140297 | 0.90 | FASN (0.49) | DDR2FASNMAPK14SLC2A1PPARG | |
| SCHEMBL6364860 | 0.89 | DDR2 (0.49) | DDR2FASNMAPK14RAB9AL3MBTL1 | |
| SCHEMBL1140747 | 0.89 | MAPK14 (0.51) | DDR2FASNMAPK14RAB9AL3MBTL1 | |
| SCHEMBL6343937 | 0.88 | DDR2 (0.47) | DDR2KDM4EMAPTFASNMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178563-B2 | Compounds and compositions as hedgehog pathway modulators | IRM LLC (BM) | 2012-05-15 | — | — | US | disclosed |
| US-20090203666-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203666-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | GLI1, SHH, SMO | DDR2 704/4885KDM4E 1129/4885MAPT 4520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.